Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q37324251)
Watch
English
Treatment of newly diagnosed myeloma.
scientific article published on 13 November 2008
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMCID
3923468
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19005483%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 January 2020
review article
1 reference
stated in
Europe PubMed Central
title
Treatment of newly diagnosed myeloma
(English)
1 reference
stated in
Europe PubMed Central
PMCID
3923468
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19005483%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 January 2020
author
S. Vincent Rajkumar
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMCID
3923468
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19005483%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 January 2020
author name string
A Palumbo
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMCID
3923468
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19005483%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 January 2020
publication date
13 November 2008
1 reference
stated in
Europe PubMed Central
PMCID
3923468
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19005483%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 January 2020
published in
Leukemia
1 reference
stated in
Europe PubMed Central
PMCID
3923468
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19005483%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 January 2020
volume
23
1 reference
stated in
Europe PubMed Central
PMCID
3923468
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19005483%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 January 2020
page(s)
449-456
1 reference
stated in
Europe PubMed Central
PMCID
3923468
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19005483%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 January 2020
issue
3
1 reference
stated in
Europe PubMed Central
PMCID
3923468
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19005483%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 January 2020
exact match
https://scigraph.springernature.com/pub.10.1038/leu.2008.325
0 references
cites work
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923468
retrieved
6 September 2017
Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923468
retrieved
6 September 2017
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923468
retrieved
6 September 2017
Improved survival in multiple myeloma and the impact of novel therapies
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923468
retrieved
6 September 2017
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923468
retrieved
6 September 2017
Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923468
retrieved
6 September 2017
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923468
retrieved
6 September 2017
The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923468
retrieved
6 September 2017
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923468
retrieved
6 September 2017
Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923468
retrieved
6 September 2017
The molecular classification of multiple myeloma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923468
retrieved
6 September 2017
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923468
retrieved
6 September 2017
Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923468
retrieved
6 September 2017
International staging system for multiple myeloma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923468
retrieved
6 September 2017
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923468
retrieved
6 September 2017
Multiple myeloma.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923468
retrieved
6 September 2017
Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923468
retrieved
6 September 2017
Review of 1027 patients with newly diagnosed multiple myeloma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923468
retrieved
6 September 2017
Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923468
retrieved
6 September 2017
Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923468
retrieved
2 September 2018
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923468
retrieved
2 September 2018
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923468
retrieved
2 September 2018
Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923468
retrieved
2 September 2018
Bortezomib inhibits human osteoclastogenesis.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923468
retrieved
2 September 2018
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923468
retrieved
2 September 2018
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923468
retrieved
2 September 2018
Thalidomide and hematopoietic-cell transplantation for multiple myeloma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923468
retrieved
2 September 2018
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923468
retrieved
2 September 2018
Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923468
retrieved
2 September 2018
Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FLEU.2008.325
retrieved
21 January 2018
Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FLEU.2008.325
retrieved
21 January 2018
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FLEU.2008.325
retrieved
21 January 2018
Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/19005483
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/19005483
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Multiple myeloma: diagnosis and treatment
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/19005483
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/19005483
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/19005483
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/19005483
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.1038/LEU.2008.325
1 reference
stated in
Europe PubMed Central
PMCID
3923468
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19005483%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 January 2020
PMCID
3923468
1 reference
stated in
Europe PubMed Central
PMCID
3923468
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19005483%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 January 2020
PubMed ID
19005483
1 reference
stated in
Europe PubMed Central
PMCID
3923468
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19005483%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 January 2020
ResearchGate publication ID
23469909
0 references
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit